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Our recent studies indicate that some derivatives of gamma-butyrolactone (GBL) possess analgesic properties in 
rodent models of pain and inflammation. Despite this pronounced biological activity, the mechanism of action of 
these GBL still remains unclear. Searching for the plausible mechanism of their action we investigated whether they 
were (similarly to nonsteroidal anti-inflammatory drugs) capable of influencing the PGE2 level in mice subjected ex-
perimentally to zymosan-induced peritonitis. The PGE2 level was evaluated in vitro by means of the ELISA assay. We 
also investigated the influence of orally administered GBL on the rat gastric mucosa in post mortem studies. We have 
demonstrated that neither of the GBL derivatives influences the PGE2 level in zymosan-induced inflammation of the 
peritoneal cavity in mice. The investigated compounds are also devoid of adverse effects within the stomach, typical 
of cyclooxygenase inhibitors, which also indirectly suggests that their analgesic and anti-inflammatory activities 
result from mechanisms other than cyclooxygenase inhibition.
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Abbreviations: AA – arachidonic acid, ASA – acetylsalicylic acid, COX – cyclooxyge-
nase, GBL – gamma-butyrolactone, GCS – glucocorticosteroids, NSAIDs – nonsteroi-
dal antiinflammatory drugs, PGE2 – prostaglandin E2, PGI2 – prostaglandin I2
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INTRODUCTION
Inflammation is an important defensive process 
in the living organisms. It involves many complex 
mechanisms that induce cellular and vascular re-
sponses and different mediators, including eico-
sanoids, histamine, free oxygen radicals and pro-
inflammatory cytokines. 
Inflammatory acute or chronic pain is one of 
the main features of inflammation (CeLotti and 
LauFer, 2001; guay et al., 2004; Khanapure et al., 
2007; KuLKarni and Singh, 2007; naM et al., 2010; 
rainSFord, 2007). The inflammatory nociception 
results from the peripheral sensitization of the 
primary nociceptive neurons. It is caused by hype-
ralgesic mediators, such as arachidonic acid (AA) 
metabolites (e.g. prostaglandins) and catechola-
mines (guay et al., 2004; LiMa et al., 2010). The 
currently used pharmacotherapy of inflammato-
ry pain comprises non-opioid analgesics, namely 
nonsteroidal anti-inflammatory drugs (NSAIDs) 
often used as first-line medications effective under 
a wide range of inflammatory and pain conditions 
(haMza and dionne, 2009; LiMa et al., 2010) and 
several groups of analgesic adjuvants, of which 
glucocorticosteroids (GCS) – potent anti-inflam-
matory agents – play a pivotal role in the therapy 
of inflammation. The most important limitation of 
the therapy using both NSAIDs and GCS is their 
ulcerogenic effect within the gastrointestinal tract 
(połać et al., 2011).
The pharmacological mechanism of analgesic 
and anti-inflammatory actions of NSAIDs is very 
well established. The inhibition of proinflamma-
tory and hyperalgesic prostaglandin synthesis 
(mainly prostaglandin E2; PGE2) results in the at-
tenuation of inflammatory symptoms and dimini-
shes the peripheral sensitization of pain. A great 
body of evidence indicates that cyclooxygenase 
(COX; prostaglandin H synthase) is a bi-functio-
nal enzyme with cyclooxygenase and peroxidase 
properties, so drugs that inhibit its function are 
thought to regulate and control the oxidative/an-
tioxidative balance and may promote antioxidant 
or pro-oxidant processes (KopFF et al., 2007). Free 
oxygen radicals, highly reactive forms of partially 
reduced oxygen, are capable of attacking various 
cellular components impairing their stability and 
proper functions. Peroxidation of lipids disrupts 
their fluidity and may cause excessive cell mem-
brane permeability, and oxidative stress plays an 
important role in the pathogenesis and progres-
sion of many diseases, including chronic pain and 
inflammation (SaLveMini et al., 2011).
Our recent studies indicate that some deriva-
tives of dihydro-furan-2-one, i.e. gamma-butyro-
lactone (GBL), possess significant analgesic pro-
perties in rodent models of pain and inflammation 
(SaLat et al., 2009; SaLat et al., 2010a; SaLat et al., 
2010b; SaLat et al., 2012a; SaLat et al., 2012b; 
wieCKowSKi et al., 2012). Despite this pronounced 
biological activity, the mechanism of action of these 
GBL remains unclear. Some hypotheses are taken 
into consideration: the influence on voltage-gated 
ion channels (anticonvulsant activity in electrical 
models of seizures and local anesthetic properties 
in mice and guinea pigs) (SaLat et al., 2009; SaLat 
et al., 2012a), anti-inflammatory activity (SaLat et 
al., 2012b) and antioxidant properties (SaLat et al., 
2012a; and our unpublished data). 
It is well known that the anti-inflammatory, an-
tipyretic and analgesic activities of NSAIDs result 
from the inhibition of COX. This, in turn, reduces 
the tissue level of AA metabolites, such as PGE2. 
Unfortunately, the same effect underlies their ir-
ritating activity on the gastric mucosa. Searching 
for the plausible mechanism of action of GBL de-
rivatives we investigated whether they were (simi-
larly to NSAIDs) capable of influencing the PGE2 
level in mice subjected to experimental model of 
zymosan-induced peritonitis. We also investigated 
the influence of GBL on the rat gastric mucosa in 
post mortem studies. 
MATERIALS AND METHODS
Drugs
Two GBL derivatives were investigated: LPP and 
LPP1. They were synthesized at the Department of 
Physicochemical Drug Analysis, Chair of Pharma-
ceutical Chemistry, Jagiellonian University, Medi-
cal College in Cracow. Their synthesis was descri-
bed earlier (SaLat et al., 2009). For the experiment 
evaluating their influence on the PGE2 level they 
were suspended in a 0.5% methylcellulose solu-
tion (Loba Chemie, Germany) and administered 
at a dose of 30 mg/kg by the intraperitoneal ro-
ute 30 min before the induction of peritoneal in-
flammation by means of zymosan. The reference 
compound – acetylsalicylic acid (ASA; Polfa Ku-
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tro, Poland) was administered orally at a dose of 
100 mg/kg 1 h before zymosan (Sigma Aldrich, 
Poland). Ketoprofen, used as a reference to inve-
stigate the ulcerogenic activity of GBL derivatives, 
was purchased from Sigma Aldrich (Poland).
Animals
Male albino Wistar rats (200-250 g) and male albi-
no Swiss (CD-1) mice (18 – 26 g) were used in the 
tests. The animals were housed and fed in a labo-
ratory kept at a constant temperature of 22°C un-
der standard conditions (12:12 h light-dark cycle, 
standard pellet diet, tap water). The experimental 
groups consisted of 6-8 animals/dose and each 
animal was used only once. The treatment of labo-
ratory animals was in full accordance with the re-
spective Polish and European regulations and was 
approved by the Local Ethics Committee of the Ja-
giellonian University in Cracow (ZI/329/2006).
Influence on the prostaglandin E2 level  
using the ELISA assay
The PGE2 level was determined by the enzyme-
linked immunosorbent assay (ELISA) in mice. The 
PGE2 level was evaluated in control animals that 
received only zymosan and in the test group (the 
group that received either LPP or LPP1 or ASA 
which was the reference compound). The ability 
of the compounds to decrease the PGE2 level was 
evaluated in the fluid isolated from the peritoneal 
cavity of mice. The experiment was divided into two 
steps: induction of acute inflammation (phase I) 
and in vitro evaluation of the PGE2 level (phase II).
Phase I: Triggering of acute inflammation  
in the mouse peritoneal cavity
To induce acute peritonitis, the animals were tre-
ated intraperitoneally with 1 mg of zymosan su-
spended in 1 ml of sterile phosphate buffer (PBS). 
After 4 h the mice were sacrificed. The peritone-
al cavity was washed with 1 ml of PBS. The flu-
id from the peritoneal cavity was centrifuged at 
800xg for 5 min. After that time the supernatant 
was collected and frozen by storing at -80 ° C until 
the determination of PGE2. 
Phase II: In vitro evaluation  
of the PGE2 level
The ELISA method is based on the competition 
between PGE2 and acetylcholinesterase conju-
gate of PGE2 (PGE2-tracer, = PGET) for a limited 
amount of monoclonal antibodies to PGE2. As the 
concentration of PGET is fixed and the concentra-
tion of PGE2 is variable, the PGET level which can 
bind to the PGE2 antibody is inversely proportio-
nal to the concentration of PGE2 in the sample. 
The antibody – PGE2 complex binds to immuno-
globulin G present in the plate of the ELISA kit. 
Then the plate is washed and the Ellman reagent 
containing the substrate for acetylcholinesterase 
is added. The product of the enzymatic reaction is 
distinctly yellow and absorbs light strongly at 412 
nm. The intensity of the color, as measured spec-
trophotometrically, is proportional to the amount 
of bound PGET, and inversely proportional to the 
amount of free PGE2.
Preparation of the standard curve
The ELISA kit (Cayman Chemicals, USA) was ap-
plied according to the manufacturer’s instruc-
tions. The absorbance of the plate was read at 412 
nm. To read the results, at the right time the ab-
sorbance of B0 sample was checked periodically. 
The proper reading of the plate was made when 
B0 absorbance reached 0.3 AU. The standard cur-
ve is a plot of % B/B0 values  (Y axis) against the 
concentration of PGE2 (in pg/ml) in the samples 
S1-S8 (X-axis).
Evaluation of the irritant action  
on the rat gastric mucosa
The ulcerogenic effect was determined according 
to the method described by KoMatSu et al. (1973). 
Twenty-four hours after oral administration of 
the compounds, the rats were sacrificed and the 
stomach was removed. After incision along the 
lesser curvature, the stomach was rinsed with 
a tap soaked in warm (37OC) saline, spread on 
a cork board and pinned down. The mucosa of 
the glandular part of the stomach was inspected 
using a binocular microscope (10-fold magnifica- 
tion). 
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Data analysis results
In the ELISA test the absorbance values  obtained 
for the standards S1-S8 and the samples contai-
ning the investigated GBL derivatives, zymosan or 
ASA were converted by the computer program into 
PGE2 concentration values. 
The mucosal lesions were evaluated using 
a five-point scale (0 – no lesions, 1 – erythema, 
2 – punctiform ulcers, 3 – small ulcers, 4 – large 
ulcers, 5 – perforation.
RESULTS
Influence of LPP, LPP1 and ASA on the PGE2 level 
determined by ELISA
For each sample (S1-S8 and the test samples) the 
% B/B0 (expressed as the percentage binding of 
the sample or the standard per maximal binding) 
were calculated. On the basis of these values ob-
tained for standards (S1-S8), the standard curve 
for the dependence between % B/B0 (Y axis) and 
the concentration of PGE2 (in pg/ml) in S1-S8 (X-
axis) was plotted using Matlab software (ver. 5) 
(Fig. 1A, 1B).
trations of PGE2 in the tested samples are shown 
in Fig. 2.
Fig. 2. Mean PGE2 concentrations in the peritoneal cavity 
fluid. 
As demonstrated above, the tested compounds 
did not decrease the PGE2 level in zymosan-indu-
ced inflammation.
Irritant action on the gastric mucosa
The influence of the investigated LPP, LPP1, ASA 
and ketoprofen on the stomach mucosa is demon-
strated in Table 1 and Fig. 3. In contrast to ASA 
(at doses of 100 and 200 mg/kg) and ketoprofen 
(50, 100 and 200 mg/kg), which caused erythe-
ma, the GBL derivatives did not damage the sto-
mach mucous membrane at any dose tested. The 
investigated compounds did not possess ulceroge-
nic activity and they did not cause microbleeding 
from the stomach mucous membrane. ASA at a 
Fig. 1A. PGE2 concentration (in pg/ml) in the peritoneal fluid 
of mice subjected to zymosan-induced inflammation.
Fig. 1B. PGE2 concentration (in pg/ml) in the peritoneal fluid 
of mice subjected to zymosan-induced inflammation.
The equation for this curve is:
y = a + b
Where:
a = -37.414
b = 110.859
From this curve, the % B/B0 values were read 
for the test samples (Fig. 1A, 1B). Average concen-
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dose of 50 mg/kg did not show ulcerogenic acti-
vity but higher doses of it caused visible erythre-
ma of the mucous membrane of the rat stomach 
(1 point on the scale). All doses of ketoprofen stron-
gly damaged the gastric mucosa (1-5 points on the 
scale for 50, 100 and 200 mg/kg, respectively).
DISCUSSION
The main aim of the present research was to in-
vestigate the mechanism of action of two GBL de-
rivatives with strong analgesic and anti-inflam-
matory activities in rodents. Since among known 
analgesic drugs NSAIDs have a similar profile of 
pharmacological activity, we first evaluated whe-
ther LPP and LPP1 were capable of reducing the 
tissue concentration of pro-inflammatory ara-
chidonic acid derivative formed by COX, namely 
PGE2. NSAIDs act by inhibiting the activity of the 
COX enzyme. Two isoforms of COX exist. COX-1 
is constitutively expressed, whereas COX-2 is an 
inducible isoform. The demonstration that the test 
compounds lower PGE2 concentration in the fluid 
from the peritoneal cavity would indirectly confirm 
that GBL derivatives inhibit the enzyme involved 
in the synthesis of this autacoid, namely COX.
PGE2, as a product of metabolism of AA, is 
present in many cells. Like most eicosanoids it is 
not stored but it is formed de novo during the in-
flammatory activation of cells and then released 
into the extracellular space. Apart from strong 
gastroprotective properties (hoShino et al., 2003), 
PGE2 is also implicated in pain sensitization and 
it has potent pro-inflammatory properties (wiL-
LiaMS, 1979). In vivo PGE2 is rapidly metabolized 
to an inactive derivative (13,14-dihydro-15-keto 
PGE2) and its biological half-life in the systemic 
circulation is about 30 s. Noteworthily, its nor-
mal level in mammalian tissues ranges between 
3-12 pg/ml. 
In order to evaluate the influence of GBL de-
rivatives on the PGE2 level, we selected two com-
pounds which possessed potent analgesic pro-
perties in rodent models of inflammatory pain. 
In our recent studies (SaLat et al., 2009; SaLat et 
al., 2012a; SaLat et al. 2012b) we showed that LPP 
and LPP1 diminished nocifensive reactions under 
inflammatory conditions and their ED50 values 
established in the writhing test (i.e. inflammatory 
pain model) were 2.4 mg/kg and 0.79 mg/kg, re-
spectively. Those values were lower than the ED50 
value for the reference compound, ASA (39.15 mg/
kg) (SaLat et al., 2009). Despite this activity profile, 
Compound Dose  [mg/kg] 
Mucosal lesions (point scale)
Erythrema  
(1) 
Punctiform 
ulcers (2)
Small ulcers
(3)
Large ulcers 
(4)
Perforation  
(5)
LPP
50 - - - - -
100 - - - - -
200 - - - - -
LPP1
50 - - - - -
100 - - - - -
200 - - - - -
ASA
50 - - - - -
100 x - - - -
200 x - - - -
Ketoprofen
50 x - - - -
100 x x x - -
200 x x x x x
TABLE 1. Influence of the compounds on the rat gastric mucosa.
The mucosa of the glandular part of the rat stomach was inspected using a binocular microscope (10-fold magnification). The mucosal lesions 
were evaluated using the 0-5 scale. 
(- = no lesions; x = presence of the effect).
Route of administration: oral
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Fig. 3. The influence of GBL derivatives and reference drugs (200 mg/kg; per os) on the rat gastric mucosa.
the immunoenzymatic ELISA assay did not con-
firm the influence of two GBL derivatives on the 
PGE2 level in our study. Therefore we may conclu-
de that the mechanism of the analgesic activity of 
LPP and LPP1 does not result from the inhibition 
of the COX enzyme.
Prostaglandins synthesized by the constitutive-
ly expressed COX-1 are implicated in the mainte-
 LPP1 200 mg/kg p.o.
 LPP1 200 mg/kg p.o.
KETOPROFEN 200 mg/kg p.o.
 ASA 200 mg/kg p.o.
CONTROL
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nance of normal physiological functions and show 
a cytoprotective action in the stomach. COX-2 
expression is normally low but it is induced by 
inflammatory stimuli and cytokines. It is thought 
that the anti-inflammatory actions of NSAIDs are 
caused by the inhibition of COX-2, whereas the 
unwanted side effects, such as gastrointestinal 
and renal toxicities, are caused by the inhibition 
of the constitutively expressed COX-1. Since the 
integral action of NSAIDs (and GCs) is their ul-
cerogenic adverse effect due to the reduced level 
of gastroprotective mediators, such as PGE2, we 
also evaluated post mortem the irritating effect of 
LPP, LPP1, ASA and ketoprofen on the rat gastric 
mucosa 24 h after the administration of the test 
compounds. Only ASA and ketoprofen damaged 
the gastric mucosa, whereas GBL derivatives did 
not. This finding can be linked to the influence or 
lack of influence of these substances on the syn-
thesis of PGE2.
It remains to be elucidated why ASA only we-
akly decreased the PGE2 level as measured by 
the ELISA assay. Several explanations should be 
considered, including very high levels of PGE2 in 
the zymosan model of inflammation and relatively 
low anti-inflammatory activity of ASA under these 
very severe inflammatory conditions. The dose of 
100 mg/kg could be insufficient to inhibit COX 
activity and decrease PGE2 generation, but it was 
high enough to exert an undesirable effect within 
the rat gastric mucosa. Available literature also 
suggests a possible involvement of metabolites 
other than PGE2 metabolites of AA (e.g. PGI2) in zy-
mosan-induced inflammation models (berKenKopF 
and weiChMan, 1988; doherty et al., 1990; yuhKi et 
al., 2008). It has to be emphasized that the level of 
PGI2 was not determined in the present study.
The fact that GBL derivatives do not decrease 
the PGE2 level is also in agreement with the obser-
vation that these compounds do not irritate the 
gastric mucosa. Neither LPP1 nor LPP showed ir-
ritancy on a five-point scale, while ASA was mode-
rately irritating (erythema at doses of 100 and 200 
mg/kg) and ketoprofen showed a strong irritating 
effect within the gastric mucosa at all three doses 
tested. Various NSAIDs show different selectivity 
against the COX-1 and COX-2 isoforms. NSAIDs 
that are relatively selective towards COX-2, such 
as meloxicam, may have an improved side-effect 
profile over non-selective NSAIDs. The potency of 
anti-inflammatory activity of ketoprofen is several-
fold higher as compared with ASA. Unfortunately, 
the irritating effect of ketoprofen on the stomach 
mucosa is also more pronounced.
Concluding, in the present study we have de-
monstrated that neither of the tested GBL deriva-
tives reduces the PGE2 level in zymosan-induced 
peritonitis in mice. These compounds are also de-
void of adverse effects within the stomach, that 
are typical of COX inhibitors, which confirms that 
their analgesic and anti-inflammatory activities 
result from other mechanisms of action. Further 
studies are necessary to investigate this issue 
more thoroughly.
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